Bromhexine

Last updated
Bromhexine
Bromhexine-PlainSVG.svg
Bromhexine-from-xtal-3D-bs-17.png
Clinical data
Trade names Bisolvon, others
AHFS/Drugs.com International Drug Names
Pregnancy
category
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 75–80%
Metabolism Extensive hepatic
Metabolites Ambroxol, others
Elimination half-life 12 hr
Excretion Urine
Identifiers
  • 2,4-Dibromo-6-{[cyclohexyl(methyl)amino]methyl}aniline
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.020.622 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C14H20Br2N2
Molar mass 376.136 g·mol−1
3D model (JSmol)
  • Brc1cc(c(N)c(Br)c1)CN(C)C2CCCCC2
  • InChI=1S/C14H20Br2N2/c1-18(12-5-3-2-4-6-12)9-10-7-11(15)8-13(16)14(10)17/h7-8,12H,2-6,9,17H2,1H3 Yes check.svgY
  • Key:OJGDCBLYJGHCIH-UHFFFAOYSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Bromhexine is a mucolytic drug used in the treatment of respiratory disorders associated with viscid or excessive mucus. [1] It was developed in the research laboratory of Boehringer Ingelheim in the late 1950s as an active ingredient for pharmaceutical use, patented in 1961, introduced in 1963 under the trademark of Bisolvon® and came into medical use in 1966. [2]

Contents

Function

Bromhexine is intended to support the body's mechanisms for clearing mucus from the respiratory tract. It is secretolytic, increasing the production of serous mucus in the respiratory tract, which makes the phlegm thinner and less viscous. This contributes to a secretomotoric effect, allowing the cilia to more easily transport the phlegm out of the lungs. For this reason it is often added to cough syrups.

It has been shown to increase the proportion of serous bronchial secretion, making it more easily expectorated. It is indicated as "secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport".

Bromhexine is contained in various formulations, high and low strength syrups 8 mg/5 ml, 4 mg/5 ml, tablets and soluble tablets (both with 8 mg bromhexine) and solution for oral use 10 mg/5 ml, adapted to the need of the patients. The posology varies with the age and weight, but there are products for all age groups from infant on. Bromhexine is well established and tolerated.

Brand names

References

  1. Morton I, Hall J (1999). Concise Dictionary of Pharmacological Agents. Springer. p. 55. ISBN   0-7514-0499-3 . Retrieved 2009-06-03.
  2. Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 544. ISBN   9783527607495.